Vitura Health Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Vitura Health yıllık ortalama 58.2% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 35.1% annual. Gelirler growing yılda ortalama 58.1% oranında artmaktadır. Vitura Health'in özkaynak karlılığı 8.5% ve net marjı 2.8%'dir.

Anahtar bilgiler

58.2%

Kazanç büyüme oranı

96.1%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	31.2%
Gelir büyüme oranı	58.1%
Özkaynak getirisi	8.5%
Net Marj	2.8%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Vitura Health nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:VIT Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	124	4	29
31 Mar 24	122	6	27
31 Dec 23	120	9	25
30 Sep 23	119	12	23
30 Jun 23	117	14	20
31 Mar 23	107	12	19
31 Dec 22	97	10	19
30 Sep 22	82	8	17
30 Jun 22	67	6	16
31 Mar 22	54	5	12
31 Dec 21	42	5	8
30 Sep 21	32	3	6
30 Jun 21	22	1	5
31 Mar 21	15	0	5
31 Dec 20	7	-2	5
30 Sep 20	4	-3	5
30 Jun 20	0	-4	4
31 Mar 20	0	-4	4
31 Dec 19	0	-4	3
30 Sep 19	0	-3	3
30 Jun 19	0	-3	3
30 Jun 18	0	0	0
30 Jun 17	0	0	0

Kaliteli Kazançlar: VIT yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: VIT 'nin mevcut net kar marjları (2.8%) geçen yılın (11.8%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VIT son 5 yılda karlı hale geldi ve kazançlarını yıllık 58.2% oranında artırdı.

Büyüme Hızlandırma: VIT 'in son bir yıldır negatif kazanç büyümesi oldu, bu nedenle 5 yıllık ortalamasıyla karşılaştırılamaz.

Kazançlar vs. Sektör: VIT geçtiğimiz yıl negatif kazanç büyümesine ( -74.6% ) sahipti ve bu da onu Pharmaceuticals sektör ortalamasıyla ( 26.6% ) karşılaştırmayı zorlaştırıyordu.

Özkaynak Getirisi

Yüksek ROE: VIT 'nin Özsermaye Getirisi ( 8.5% ) düşük olarak değerlendiriliyor.

Vitura Health Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 2/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Full year 2023 earnings released: EPS: AU$0.025 (vs AU$0.012 in FY 2022)

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Recent updates

Vitura Health Limited Announces Director Appointments

Crisci Group and Vitura Health Limited (ASX:VIT) acquired Assets of Releaf Group from Releaf Group Ltd for AUD 6.07 million .

Vitura Health Limited Announces Step Down of Directors

Now 22% undervalued

Vitura Health Limited Appoints Stefan Schmidt as Chief Technology Officer

Vitura Health Limited, Annual General Meeting, Nov 27, 2024

New minor risk - Profit margin trend

Vitura Health Limited Resolves Not to Pay A Dividend in Respect of the Year Ended 30 June 2024

Less than half of directors are independent

Board Member recently sold AU$1.1m worth of stock

First half 2024 earnings released: EPS: AU$0.006 (vs AU$0.014 in 1H 2023)

Now 39% undervalued after recent price drop

Vitura Health Limited Receives Shareholder Requisition from Elizabeth Sarah Jansen

Vitura Health Limited (ASX:VIT) completed the acquisition of acquire an unknown stake in Doctors on Demand from Yeates Ventures Pty Ltd and Kirsty Garrett.

New minor risk - Shareholder dilution

Vitura Health Limited, Annual General Meeting, Nov 28, 2023

Upcoming dividend of AU$0.01 per share at 2.7% yield

Vitura Health Limited Announces Dividend for the Year Ended 30 June 2023, Payable on or Around, 28 September 2023

Full year 2023 earnings released: EPS: AU$0.025 (vs AU$0.012 in FY 2022)

New minor risk - Financial data availability

Insider recently sold AU$2.3m worth of stock

Chief Commercial Officer recently sold AU$5.9m worth of stock

Chief Operating Officer recently sold AU$2.6m worth of stock

High number of new and inexperienced directors

Cronos Australia Limited Announces Changes to Clinical Operations

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Board Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Cronos Australia Limited Announces Ceases of Benjamin D.N. Jansen as Chief Medical Officer

Cronos Australia Limited Provides Update on Canview 2.0 Platform

Cronos Australia Limited, Annual General Meeting, Nov 29, 2022

Cronos Australia Limited Appoints Jenelle Frewen and Simone Scovell as Independent Non-Executive Director

Cronos Australia Limited Announces Dividend for the Year Ended 30 June 2022, Dividend Payment Date Is 11 October 2022

Full year 2022 earnings released: EPS: AU$0.013 (vs AU$0.031 loss in FY 2021)

Cronos Australia Limited to Report Q2, 2022 Results on Jul 27, 2022

Cronos Australia Announces Resignation of Shane Tanner, Chairman and Director

Cronos Australia Limited Announces Resignation of Kurt Thomas Schmidt as Director

First half 2022 earnings: Revenues and EPS in line with analyst expectations

High number of new directors

Cronos Australia Limited (ASX:CAU) completed the acquisition of Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited (ASX:CAU) entered into Merger implementation agreement to acquire Cannabis Doctors Australia Pty Ltd.

Cronos Australia Limited Announces Launch of Additional Products in Key Asian Markets

Cronos Australia Limited Provides Revenue Guidance for the Fourth Quarter of 2021

Cronos Australia Limited Announces Launch of First Personal Care Brand in North Asian Markets with Bathing Shed

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin